143 related articles for article (PubMed ID: 23725458)
1. AKT-ing out: SGK kinases come to the fore.
Moniz LS; Vanhaesebroeck B
Biochem J; 2013 Jun; 452(3):e11-3. PubMed ID: 23725458
[TBL] [Abstract][Full Text] [Related]
2. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Sommer EM; Dry H; Cross D; Guichard S; Davies BR; Alessi DR
Biochem J; 2013 Jun; 452(3):499-508. PubMed ID: 23581296
[TBL] [Abstract][Full Text] [Related]
3. Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer.
Sahoo S; Brickley DR; Kocherginsky M; Conzen SD
Eur J Cancer; 2005 Nov; 41(17):2754-9. PubMed ID: 16246546
[TBL] [Abstract][Full Text] [Related]
4. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
[TBL] [Abstract][Full Text] [Related]
6. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SGK1 enhances mAR-induced apoptosis in MCF-7 breast cancer cells.
Liu G; Honisch S; Liu G; Schmidt S; Pantelakos S; Alkahtani S; Toulany M; Lang F; Stournaras C
Cancer Biol Ther; 2015; 16(1):52-9. PubMed ID: 25427201
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?
Prêtre V; Wicki A
Semin Cancer Biol; 2018 Feb; 48():70-77. PubMed ID: 28473255
[TBL] [Abstract][Full Text] [Related]
9. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
12. Activation of SGK1 in Endometrial Epithelial Cells in Response to PI3K/AKT Inhibition Impairs Embryo Implantation.
Salker MS; Steel JH; Hosseinzadeh Z; Nautiyal J; Webster Z; Singh Y; Brucker S; Lang F; Brosens JJ
Cell Physiol Biochem; 2016; 39(5):2077-2087. PubMed ID: 27825168
[TBL] [Abstract][Full Text] [Related]
13. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
14. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
15. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
16. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
17. Second AKT: the rise of SGK in cancer signalling.
Bruhn MA; Pearson RB; Hannan RD; Sheppard KE
Growth Factors; 2010 Dec; 28(6):394-408. PubMed ID: 20919962
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).
Brunet A; Park J; Tran H; Hu LS; Hemmings BA; Greenberg ME
Mol Cell Biol; 2001 Feb; 21(3):952-65. PubMed ID: 11154281
[TBL] [Abstract][Full Text] [Related]
19. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
20. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
Jabbarzadeh Kaboli P; Salimian F; Aghapour S; Xiang S; Zhao Q; Li M; Wu X; Du F; Zhao Y; Shen J; Cho CH; Xiao Z
Pharmacol Res; 2020 Jun; 156():104806. PubMed ID: 32294525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
